VICTORIA, British Columbia / Dec 15, 2025 / Business Wire / MindWalk (NASDAQ: HYFT), a BioNative AI biotherapeutic research and technology company combining in silico and wet lab operations for biologics discovery and development, today announced financial results for the second quarter of fiscal 2026 and provided updates on its AI driven asset pipeline and strategic initiatives. MindWalk operates a proprietary BioNative AI... Read More

The Company to host an earnings conference call via webcast AUSTIN, Texas / Dec 08, 2025 / Business Wire / MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for second quarter fiscal year 2026, on Monday, December 15, 2025, at 10:30... Read More

AUSTIN, Texas / Nov 13, 2025 / Business Wire / MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company, today announced that Dr. Dirk Van Hyfte, Chief Technology Officer, will participate in a fireside chat during the Biology Session at the AI Drug Discovery & Development Summit 2025, taking place on November 20, 2025, from 12:15 PM to 12:45 PM. The AI Drug Discovery &... Read More

AUSTIN, Texas / Oct 21, 2025 / Business Wire / MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), bio-native AI company today announces the appointment of industry veteran R. Scott Areglado as Chief Financial Officer (CFO), effective October 20, 2025. “Scott’s extensive experience leading financial strategy for high-growth, publicly traded healthcare and technology companies makes him an ideal... Read More

AUSTIN, Texas / Oct 15, 2025 / Business Wire / MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company today announced the appointment of industry veteran Thomas W. Lynch, Ph.D. as Chief Business Officer (CBO), effective October 20, 2025. “Tom’s combination of biotech depth and software commercialization expertise directly supports MindWalk’s next path of growth,” said Dr.... Read More

AUSTIN, Texas / Oct 09, 2025 / Business Wire / MindWalk Holdings Corp. (“MindWalk” or the “Company”) (NASDAQ: “HYFT”), a bio-native AI company, today announced that to underscore its confidence in MindWalk's future development and growth prospects, its Board of Directors (the “Board”) has authorized a share repurchase program under which MindWalk may repurchase up to 2.3 million common shares of the Company, no par value... Read More

Company builds on earlier GLP-1 success with breakthrough AI-led insights into aging biology -- targeting the widely projected $60B longevity therapeutics market HYFT®-driven discovery supports co-administration of MindWalk’s proprietary companion therapeutic with the Company’s GLP-1 receptor agonist AUSTIN, Texas / Sep 22, 2025 / Business Wire / MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT),... Read More

Company to hold conference call on September 15, 2025, at 10:30 ET to review corporate highlights AUSTIN, Texas / Sep 15, 2025 / Business Wire / MindWalk Holdings Corp.™ (“MindWalk™”, “Company”, “we” or “us”) (NASDAQ: HYFT), a Bio-Native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced financial results for its first fiscal quarter of 2026, ended July 31, 2025. All... Read More

The Company to host an earnings conference call via webcast AUSTIN, Texas / Sep 10, 2025 / Business Wire / MindWalk (NASDAQ: HYFT) (“HYFT” or the “Company”), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year end 2026, on Monday,... Read More

An Evolution in Name, Structure, and Strategy Reflecting the Company’s AI-Driven Platform and Bio-Native Discovery Vision AUSTIN, Texas / Sep 03, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), ImmunoPrecise Antibodies Ltd. and its subsidiaries (BioStrand and Talem) today announced a unification under a single corporate brand, MindWalk , and a change of its Nasdaq ticker symbol to... Read More

AUSTIN, Texas / Sep 02, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), today announced that it will participate in the 27th Annual H.C. Wainwright Global Investment Conference, taking place September 8 th through September 10 th , 2025. Dr. Jennifer Bath, President CEO of IPA, will deliver a company presentation and be available for one-on-one investor meetings throughout the... Read More

Manufacturing of validated dengue epitope underway; proprietary immunization studies in rabbit model to assess monoclonal antibody (mAb) responses. AUSTIN, Texas / Aug 27, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a biotherapeutics company delivering advanced solutions in biologics and drug discovery today announced the next milestone in its universal dengue vaccine program.... Read More

AUSTIN, Texas / Aug 06, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a biotherapeutics company delivering advanced solutions in biologics and drug discovery, today announced the successful sale of its Netherlands-based subsidiary, ImmunoPrecise Antibodies (Europe) B.V. (“IPA Europe”), to AVS Bio for a total enterprise value of $12 million USD. AVS Bio, a portfolio company of... Read More

AUSTIN, Texas / Jul 29, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (“IPA”, “Company”, “we” or “us”) (NASDAQ: IPA), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announces its financial results for the fiscal year ended April 30, 2025. All numbers are expressed in Canadian dollars unless otherwise noted. Financial Highlights: Achieved strong revenue for... Read More

AUSTIN, Texas / Jul 24, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a Bio-Native AI pioneer operating where TechBio meets true biological intelligence, today announced results of a newly expanded study demonstrating that its LENS ai ™ Immunogenicity Screening can reliably predict Anti-Drug-Antibody (ADA) risk for therapeutic proteins before they enter animal studies or human... Read More

AUSTIN, Texas / Jul 21, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced the appointment of Jeff Fried to its Advisory Board. A recognized leader in healthcare data infrastructure and AI innovation, Jeff Fried brings more than 25 years of experience designing and... Read More

The Company to host an earnings conference call via webcast AUSTIN, Texas / Jul 16, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for fourth quarter and full fiscal... Read More

AUSTIN, Texas / Jul 14, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a company operating at the convergence of TechBio and biological intelligence, today announced that it has received formal notification from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), concerning the minimum bid price... Read More

AUSTIN, Texas / Jul 07, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), an AI-powered biotherapeutics company, today announced the appointment of Jon Lieber to its Board of Directors, effective immediately. Mr. Lieber brings over 30 years of financial and strategic leadership across the biotechnology and life sciences sectors, with deep expertise in capital markets, investor... Read More

New benchmark confirms LENS ai ’s ability to accurately predict binding on 17 previously unseen antibody-antigen complexes, achieving near-crystallography precision without prior training data. AUSTIN, Texas / Jul 03, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd . (NASDAQ: IPA) (“IPA” or the “Company”), an AI-powered biotherapeutics company, today announced a new validation study supporting the generalizability of its... Read More

Follow-Up to June 5, 2025, Announcement Demonstrates Validated Vaccine Candidate with Strong Translational Potential AUSTIN, Texas / Jun 24, 2025 / Business Wire / ImmunoPrecise (NASDAQ: IPA), a leader in AI-driven biotherapeutics, provides a significant update following its June 5, 2025, press release ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery . This new release details the... Read More

Breakthrough in AI-powered drug discovery validates HYFT™-driven peptide design, with broad potential across multiple therapeutic areas AUSTIN, Texas / Jun 12, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) , a leader in AI-powered drug discovery and biotherapeutics, today announced compelling in vitro results demonstrating that its artificial intelligence (AI)-designed GLP-1 receptor agonist (GLP-1RA)... Read More

LENS ai ™ powered by HYFT® technology Identifies a single multi-factorial target conserved across all dengue serotypes. AUSTIN, Texas / Jun 05, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, announces discovery of a highly conserved epitope across all four dengue virus serotypes using its proprietary LENS ai ™ platform powered by their patented HYFT® technology.... Read More

AUSTIN, Texas / May 21, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) a leader in AI-driven biotherapeutics, today announced it has engaged CORE IR, a strategic investor and public relations firm, to support the Company’s ongoing investor relations and communications initiatives. CORE IR specializes in working with emerging and established growth companies to enhance investor awareness, strengthen... Read More

Tuesday, June 3rd at 11:00 a.m. EDT AUSTIN, Texas / May 20, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) a leader in AI-driven biotherapeutics, today announced that Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies Ltd., will be presenting at the Maxim Group’s virtual conference: 2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow Hosted by: Maxim Group LLC Date: June 3 rd –... Read More

AUSTIN, Texas / May 12, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, is pleased to announce today new benchmarking results that validate the accuracy and utility of its in silico epitope mapping application, part of the LENS ai ™ platform, with a direct comparison to gold-standard wet-lab methods. The results represent a notable advancement in computational... Read More

AUSTIN, Texas / Apr 11, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) a leader in AI-driven biotherapeutics, today announced its strong support for the U.S. Food and Drug Administration’s (FDA) recent decision to phase out animal testing requirements for monoclonal antibodies and other pharmaceutical products. The FDA’s announcement marks a significant advancement in regulatory modernization and... Read More

Secures $8-$10M Strategic Partnership Scales AI Infrastructure Collaborations with Vultr and Leading Providers of Advanced GPU technologies to Accelerate de novo Drug Discovery. Unlocking Margin Expansion Through Scalable AI IPA Strengthens Board & Management Team Kamil Isaev, Joseph Scheffler, and Dr. Li Hui join IPA, enhancing leadership in AI, finance, and client relations. AUSTIN, Texas / Mar 28, 2025 / Business Wire /... Read More

Programs to be Driven Through Patented AI Technology and Advanced Proprietary B Cell Platforms Partnership advances next-generation ADCs and bispecific antibodies to address unmet medical needs AUSTIN, Texas / Mar 13, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) is pleased to announce a strategic partnership with a leading biotechnology company with a multi-billion-dollar market capitalization to... Read More

The Company to host an earnings conference call via webcast AUSTIN, Texas / Mar 11, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody discovery and development, today announces the rescheduling of its Third Quarter Fiscal 2025 financial results and business highlights release. Originally set for March 13, 2025, the new release date is Friday,... Read More

The Company to host an earnings conference call via webcast AUSTIN, Texas / Mar 05, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody discovery and development, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for third quarter fiscal year 2025, on Thursday, March 13, 2025, at... Read More

AUSTIN, Texas / Feb 26, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody discovery and development, today announced a strategic collaboration with RIBOPRO, a pioneering technology provider specializing in mRNA and lipid nanoparticle (LNP) technologies. This collaboration seeks to revolutionize the discovery and development of therapeutic... Read More

AUSTIN, Texas / Feb 24, 2025 / Business Wire / ImmunoPrecise Antibodies (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce key leadership updates, including the appointment of Kamil Isaev to its Board of Directors and Joseph Scheffler as Interim Chief... Read More

AUSTIN, Texas / Feb 20, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody discovery and development, today announced that its application to transfer its securities to the Nasdaq Capital Market has been approved by Nasdaq Listing Qualifications. This transition allows IPA an additional 180-day compliance period, until August 18, 2025, to meet... Read More

IPA Successfully Executes Strategic Capital Initiatives, Strengthening Financial Position for Growth AUSTIN, Texas / Jan 27, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (“IPA” or the “Company”) (NASDAQ: IPA), a leader in AI-driven antibody discovery and development, today announced the successful completion of its previously disclosed USD $8.8 million “at-the-market” equity offering program (the “ATM Program”)... Read More

AUSTIN, Texas / Jan 22, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) has developed a new class of GLP-1 therapies entirely through artificial intelligence, designed to enhance efficacy, safety, therapy longevity, and patient satisfaction in diabetes treatment. These AI-designed therapeutics aim to... Read More

AUSTIN, Texas / Jan 17, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) today announced the launch of its AI-powered pipeline of both optimized and new therapeutics, a system set to transform therapeutic development. By combining advanced artificial intelligence with first-principles thinking, the BioStrand pipeline reimagines drug discovery, offering unmatched speed, precision, and transparency.... Read More

AUSTIN, Texas / Dec 31, 2024 / Business Wire / ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) today announced that Kristin Taylor has resigned from her position as Chief Financial Officer effective January 16, 2025. Ms. Taylor will continue to serve in the role of CFO until January 16, 2025, and will remain available to the company on a consulting basis after that time. “Kristin has been a valued member of our team over... Read More

VICTORIA, British Columbia / Dec 23, 2024 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce significant insider activity, with key members of its executive team and subsidiary co-founders demonstrating confidence in the Company’s strategic direction and long-term potential through substantial share... Read More

VICTORIA, British Columbia / Dec 19, 2024 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced is pleased to announce its participation in The Microcap Conference 2025 , the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, in Atlantic City, NJ.... Read More

Delivers $6.1 Million Q2 Revenue and Announces Strategic Plan to Reshape Biotech and AI-Driven Drug Discovery VICTORIA, British Columbia / Dec 10, 2024 / Business Wire / IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today reported financial results for the second quarter (“Q2”) of its 2025 fiscal year (“FY25”), which ended October 31, 2024.... Read More

VICTORIA, British Columbia / Dec 04, 2024 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced it will be presenting at The Benchmark Company’s 13 th Annual Discovery One-on-One Investor Conference to be held Wednesday, December 11 th , 2024, at the New York Athletic Club in New York City. The conference... Read More

The Company to host an earnings conference call via webcast VICTORIA, British Columbia / Dec 03, 2024 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for second quarter fiscal year 2025, on Tuesday,... Read More

Innovative Antibodies Show Promise for Antibody-Drug Conjugate (ADC) Development, Paving the Way for Transformative Cancer Treatments VICTORIA, British Columbia / Nov 13, 2024 / Business Wire / ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), a leader in AI-driven medical innovation, is proud to announce a significant breakthrough in its primary cancer research initiatives. This accomplishment not only... Read More

VICTORIA, British Columbia / Nov 04, 2024 / Business Wire / ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, announces the details of its upcoming TECHDAY event on Friday, November 15, 2024, from 9:00 a.m. to 12:30 p.m. EST in Cambridge, Massachusetts. This exclusive gathering will highlight IPA’s latest advancements in AI-driven design,... Read More

Rabbit B Cell Select® Platform Yields Novel Antibodies for Studying Age-Related Mitochondrial Dysfunction VICTORIA, British Columbia / Oct 28, 2024 / Business Wire / ImmunoPrecise Antibodies Ltd. ("IPA" or the "Company") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, announces its significant contribution to a groundbreaking study. The research, led by top scientists at the Mayo Clinic, was... Read More

VICTORIA, British Columbia / Oct 21, 2024 / Business Wire / ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that Dr. Dirk Van Hyfte, Head of Innovation at BioStrand, IPA’s AI subsidiary, will participate on a Fireside Chat during the AI Driven Drug Discovery Summit USA 2024 taking place at the Aloft Boston Seaport District... Read More

University of Washington’s Baker Lab and Google DeepMind Redefine Protein Science, Paving the Way for AI-Driven Biotherapeutics VICTORIA, British Columbia / Oct 10, 2024 / Business Wire / ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today celebrates the recent Nobel Prize in Chemistry awarded to David Baker of the University of Washington,... Read More

Talem Therapeutics' Antibody Asset to be Evaluated for Bispecific Development Against Solid Tumors VICTORIA, British Columbia & ZHUHAI, China / Oct 02, 2024 / Business Wire / ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, and Biotheus Inc. (Biotheus), a clinical-stage biotech company dedicated to the discovery and development of biologics for... Read More

Rabbit B Cell Select ® Drives Clinical Breakthroughs in Cancer Treatment VICTORIA, British Columbia / Sep 26, 2024 / Business Wire / ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today proudly announces the clinical progress achieved with rabbit monoclonal antibodies... Read More

Achieves $5.3 Million First Quarter Revenue, Reaches Milestone Developing Antibodies End-to-End Using LENS ai VICTORIA, British Columbia / Sep 16, 2024 / Business Wire / IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today reported financial results for the first quarter of its 2025 fiscal year (“FY25”), which ended July... Read More

The Company to host an earnings conference call via webcast VICTORIA, British Columbia / Sep 09, 2024 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year... Read More

VICTORIA, British Columbia / Aug 26, 2024 / Business Wire / ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), is pleased to announce that it will be attending H.C. Wainwright's 26th Annual Global Investment Conference (the "Global Investment Conference"). The Company's management team invites shareholders and all interested parties to attend. Admission to the Global Investment Conference is free to... Read More

VICTORIA, British Columbia / Aug 23, 2024 / Business Wire / ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutics company, announced today that the Company received written notification (the " Notification Letter ") from the Nasdaq Global Market LLC (" Nasdaq ") on August 19, 2024, indicating that the Company is not in compliance with the minimum bid price requirement set forth in... Read More

Engineering antibodies in silico using LENS ai™ marks a significant milestone toward the complete de novo design of antibodies, aligning with IPA's vision to make groundbreaking and safer therapeutics instantly accessible and affordable. Key takeaways: Highly Specific Binding of Novel Antibodies to a Tumor Microenvironment Protein of Previously Unknown Structure - Verified in Laboratory Setting. The Targeted Protein,... Read More

Achieves Record $24.5 Million Revenue in FY 2024, Showcases Technological Advancements Expands Laboratory Capabilities and Launches Advanced AI Models, Aimed at Strengthening Market Position Launches Commercial LENS ai API, Offering Advanced AI-Powered Solutions Across Multiple Markets and Prepares for Further Launch with its Newest Partner, AWS VICTORIA, British Columbia / Jul 29, 2024 / Business Wire / ImmunoPrecise... Read More

The Company to host an earnings conference call via webcast VICTORIA, British Columbia / Jul 23, 2024 / Business Wire / ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA) today announces the rescheduling of its full year fiscal 2024 financial results and business highlights release. Originally set for July 25, 2024, the new release date is Monday, July 29, 2024, and will hold an earnings call at 10:30 am... Read More

VICTORIA, British Columbia / Jul 16, 2024 / Business Wire / ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that it has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global, LP (“Yorkville”), under which the Company agreed... Read More

The Company to host an earnings conference call via webcast VICTORIA, British Columbia / Jul 15, 2024 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, will announce its full year fiscal 2024 financial results and business highlights on Thursday, July 25, 2024, and will hold an earnings call at 10:30 am Eastern Time the... Read More

VICTORIA, British Columbia / Jun 27, 2024 / Business Wire / ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce the appointment of Kristin Taylor as Chief Financial Officer, effective immediately. Ms. Taylor has been serving as Interim CFO since September 19th, 2023, and now transitions into the role on a permanent basis.... Read More

VICTORIA, British Columbia / Jun 25, 2024 / Business Wire / ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that its subsidiary, BioStrand, is collaborating with PGxAI to leverage BioStrand's patented Foundation AI Model, LENS ai . This collaboration advances the precision medicine field of pharmacogenomics and supports LENS ai... Read More

VICTORIA, British Columbia / Jun 12, 2024 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, today announces that its subsidiary, BioStrand, has been honored with the prestigious 2024 Impact Award, sponsored by InterSystems. This recognition highlights BioStrand’s groundbreaking work in biotherapeutic... Read More

BioStrand now offers a Customizable Application Programming Interface (API) with its new software offering, LENS ai API, featuring the ability to integrate sizable databases and electronic health records with large language models. BioStrand’s novel software is rapidly and directly integrable into pharmaceutical, healthcare, and technology companies to enhance drug discovery capabilities. This proprietary software provides... Read More

Dirk Van Hyfte MD, PhD, Head of Technology, IPA, to present live demonstration at the InterSystems Global Summit 2024 June 9-12, 2024 - National Harbor, Maryland VICTORIA, British Columbia / Jun 04, 2024 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today announced that its Belgian subsidiary,... Read More

VICTORIA, BC / ACCESSWIRE / April 22, 2024 / ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, has recently announced an expansion of its already successful LENS ai TM Platform. LENS ai , which is run by the company's subsidiary, BioStrand, provides a unique and comprehensive view of life sciences data by linking sequence, structure, function and literature information... Read More

VICTORIA, BC / ACCESSWIRE/ April 12, 2024 / InterSystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability and speed challenges partnered with ImmunoPrecise Antibodies (NASDAQ:IPA) ("IPA"), an artificial intelligence-driven biotherapeutic research and technology company in what they stated is a landmark collaboration. Between June 2022 and March 2023,... Read More

VICTORIA, British Columbia / Mar 28, 2024 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), InterSystems , a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability, and speed challenges, together with ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and... Read More

Significant throughput of LSA to advance IPA’s diversity- and data-driven drug development and to enrich LENS ai™ . VICTORIA, British Columbia / Mar 20, 2024 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today announced that it has acquired the LSA ® instrument platform from Carterra ® , a leading... Read More

IPA reports a fourth consecutive quarter of increased revenue. VICTORIA, British Columbia / Mar 14, 2024 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today reported financial results for its third quarter of the 2024 fiscal year (“FY24”), which ended January 31, 2024. “ImmunoPrecise Antibodies... Read More

Dirk Van Hyfte MD, PhD, Co-Founder and Head of Innovation of BioStrand, to present findings live next week at the HIMSS24 conference in Orlando, Florida VICTORIA, British Columbia / Mar 07, 2024 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today announced the development of a Foundation AI Model... Read More

The Company to host an earnings conference call via webcast. VICTORIA, British Columbia / Mar 04, 2024 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for third fiscal year 2024, on... Read More

VICTORIA, British Columbia / Dec 14, 2023 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today reported financial results for its second quarter of the 2024 fiscal year (“FY24”), which ended October 31, 2023. "We report our third consecutive quarter of record revenue, reflecting both existing and... Read More

VICTORIA, British Columbia / Dec 08, 2023 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), today announced the closing of its $1.265 million underwritten public offering of 1,265,000 common shares, including 165,000 common shares issued pursuant to the full exercise by the underwriter of its over-allotment option. The public offering price for each common share,... Read More

VICTORIA, British Columbia / Dec 06, 2023 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”) today announced that it has priced its underwritten public offering of 1,100,000 common shares at a public offering price of $1.00 per share. All common shares in the underwritten public offering are to be sold by the Company. The Company expects the aggregate gross proceeds from... Read More

VICTORIA, British Columbia / Dec 05, 2023 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), today announced that it intends to offer and sell common shares in an underwritten public offering. All of the common shares in the underwritten public offering are to be sold by the Company. The Company also expects to grant the underwriters a 30-day option to purchase up to an... Read More

VICTORIA, British Columbia / Nov 27, 2023 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is pleased to announce important Board of Director changes and upcoming financial reporting activities. New Board Chairman Mitch Levine joined the Board of Directors of IPA at IPA’s recent Annual General Meeting and... Read More

VICTORIA, British Columbia / Nov 13, 2023 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is thrilled to announce that its subsidiary, BioStrand®, has published a preprint of its groundbreaking white paper titled, "New Paradigm for Biological Sequence Retrieval Inspired by Natural Language Processing and... Read More

BioStrand Unveils Groundbreaking Retrieval Augmented Generation (RAG)-Based LLM Platform Integrated with Patented HYFT Technology BioStrand's Work Exemplifies the IPA Family's Investment in Advanced AI, Aiding Partners in Developing New Biologics for Previously Undruggable Targets VICTORIA, British Columbia / Oct 25, 2023 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the... Read More

VICTORIA, British Columbia / Oct 23, 2023 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), an AI-driven biotherapeutic research and technology company wishes to provide an update on its overall growth strategy, particularly in light of recent market developments. IPA remains committed to expanding its contract research organization (CRO) capabilities and leveraging technology to drive... Read More

Brad McConn to Step Down Later This Month Kristin Taylor, MBA, CPA, Named Interim CFO VICTORIA, British Columbia / Sep 19, 2023 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), today announced that it has accepted the resignation of Brad McConn, CFO, effective September 29, 2023. IPA has named Kristin Taylor, MBA, CPA, as interim Chief Financial Officer. “On behalf of IPA, I thank... Read More

Company recorded record quarterly revenue, an increase of 21.3% compared to the same quarter last year. Significantly higher net income before taxes when compared to Q1 of last year, a difference of approximately $6 million dollars, another positive back-to-back quarter trend. VICTORIA, British Columbia / Sep 14, 2023 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven... Read More

The Company to host an earnings conference call via webcast VICTORIA, British Columbia / Sep 08, 2023 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year 2024, on Thursday,... Read More

IPA appoints Barry A. Springer, Dirk Witters and Chris Buyse to the Board of Directors VICTORIA, British Columbia / Sep 05, 2023 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “ Company ” or “ IPA ”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, is pleased to announce that further to its news release dated August 9, 2023, it has appointed, in its search for optimal Board composition,... Read More

IPA responds to 13D Filing by Ingalls & Snyder, LLC VICTORIA, British Columbia / Aug 09, 2023 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today issued the following statement in response to the Schedule 13D filing made on July 7, 2023 by Ingalls & Snyder, LLC a New York-based investment manager. "IPA’s Board of... Read More

VICTORIA, British Columbia / Jul 14, 2023 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), an AI-driven biotherapeutic research and technology, is delighted to extend an invitation to investors and other interested parties to participate in an upcoming interview hosted by Market Radius Research. Martin Gagel, founder of Market Radius Research, will join forces with Dr. Jennifer Bath,... Read More

The Company achieved revenue of $20.7 million during the year ended April 30, 2023, a 6.7% increase from the year ended April 30, 2022. YoY growth increases to 9.0% when adjusting for the effects of currency translation. The Company recorded total revenue of $5.6 million during the three months ended April 30, 2023, the highest quarterly revenue total the Company has recorded. VICTORIA, British Columbia / Jul 07, 2023 /... Read More

The Company to host an earnings conference call via webcast VICTORIA, British Columbia / Jun 29, 2023 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), a leader in AI-driven biotherapeutic research and technology, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for fourth quarter and fiscal year end 2023, on... Read More

VICTORIA, British Columbia / Jun 13, 2023 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is excited to announce a new use case for the Information Integration Dilemma (IID) solution developed by its subsidiary, BioStrand®. Link to use case here The IID has long been a significant challenge in the biotechnology industry,... Read More

VICTORIA, British Columbia / Jun 06, 2023 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”) today introduced a transformative AI-driven rapid therapeutic screening platform, the result of a collaboration between IPA Canada and its subsidiary, BioStrand®. This innovative solution aims to... Read More

VICTORIA, British Columbia / May 30, 2023 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), an AI-driven biotherapeutic research and technology company, today announced that its subsidiary, BioStrand®, has successfully solved the Information Integration Dilemma (IID) by developing a unique technology design that enables their patented HYFT Technology to encapsulate and... Read More

VICTORIA, British Columbia / May 17, 2023 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”) an AI-driven biotherapeutic research and technology company today announced that Dr. Jennifer Bath, the company's Chief Executive Officer and President, will present at the Jefferies Healthcare Conference on Friday June 9, 2023, at 11:00 a.m. Eastern time. The live and archived... Read More

Agreement Focuses on in silico and de novo Discovery and Development of Antibodies Against Tumor Microenvironment Targets. Program will Leverage BioStrand’s (a Talem Affiliate) LENSai® Integrated Intelligence Technology® , Built Upon the Proprietary HYFT Index®. VICTORIA, British Columbia / Mar 30, 2023 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”) an AI-driven... Read More

Company Received Official Notice from the European Patent Office (EPO) for the Decision to Grant its Patent Application on April 5 th , 2023. The Patent was Initially Filed February 7 th , 2020. Patent Application Covers a Method to Efficiently Handle Mass Biological Sequence Information. Related Patents Pending in Other Countries, Favorable Outcomes Anticipated VICTORIA, British Colombia / Mar 27, 2023 / Business Wire /... Read More

Company to Present at the Upcoming 2023 Annual Meeting of the American Association for Cancer Research (AACR) ImmunoPrecise’s Unique Proprietary Bispecific Antibodies Link Cells Expressing Tumor-Associated Antigen Tropomyosin Receptor Kinase B (TrkB) with CD3-Positive T Cells, Immune System Cells that Respond by Recognizing and Eliminating Cancer Cells. The Company’s Potential Therapeutic, which is Designed to Bring... Read More

VICTORIA, British Columbia / Mar 16, 2023 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for third quarter fiscal year 2023, which ended January 31, 2023. “We are thrilled to announce that this quarter has been a foundational one for our company. Our project revenue has experienced a... Read More

VICTORIA, British Columbia & SANTIAGO DE COMPOSTELA, Spain / Mar 15, 2023 / Business Wire / Immunoprecise Antibodies Ltd. (NASDAQ: IPA) (“Immunoprecise” or “IPA” or the “Company”), an AI-driven biotherapeutic research and technology company, today announced that Talem Therapeutics LLC, an independently operating subsidiary of IPA, and Libera Bio S.L., have signed a collaboration agreement to jointly address intracellular... Read More

VICTORIA, British Columbia / Mar 07, 2023 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for third quarter fiscal year 2023, on Thursday, March 16, 2023, at 10:30 am Eastern Time. The financial results... Read More

Structural HYFT Technology is used as a navigational layer to parse over the protein predictive platforms AlphaFold-2 and Evolutionary Scale Modeling (ESM)-2 Fold HYFT Technology explores formal and explicit biologically relevant knowledge and connects information about sequence, structure, and function HYFT Technology is continuously enriched, e.g., by the structural models released by ESM-2 Fold and AlphaFold-2 HYFTs are... Read More

Under strategic collaboration, Talem, an IPA subsidiary, expands its relationship with Ligand/OmniAb, Inc., to develop three immuno-oncology programs targeting validated targets Talem intends to leverage IPA’s broad range of advanced laboratory and in silico computational technologies, including LENSai ™ Antibodies were discovered using OmniChicken antibody discovery technology Immunoprecise Antibodies (the “Company” or... Read More

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), announced today that its subsidiary, Talem Therapeutics LLC (“Talem”), has shared positive results of a new study conducted by the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), that has shown the continued resilience of PolyTope® TATX-03 in broadly neutralizing SARS-Co-V-2... Read More

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced financial results for first quarter fiscal year 2023, which ended July 31, 2022. “Our biggest surprise this quarter was how rapidly our iterative-feedback AI software platform for antibody discovery advanced toward commercialization,” stated Dr. Jennifer Bath,... Read More

ImmunoPrecise Antibodies (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year 2023, on Wednesday, September 14, 2022, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call.... Read More

IPA ( IMMUNOPRECISE ANTIBODIES LTD .) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), a biotherapeutic research and technology company, today announced the continuing success of PolyTope® TATX-03 antibody combination therapy to neutralize variants of concern of the COVID-19 causative virus, including the latest Omicron BA.5 subvariant, validated by an independent research organization in an authentic virus assay.... Read More

IPA ( IMMUNOPRECISE ANTIBODIES LTD .) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced financial results for the full fiscal year 2022 ended April 30, 2022. Fiscal 2022 Financial Summary* The Company achieved record total revenues of $19.4 million during the year ended April 30, 2022, an 8.1% increase from the year ended April 30, 2021. Project... Read More

ImmunoPrecise Antibodies (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its financial results and recent business highlights for fourth quarter and full fiscal year 2022, on Friday, July 29, 2022, at 10:30 am Eastern Time. The financial results will be issued in a... Read More

ImmunoPrecise Antibodies (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, reports the critical third-party findings of two IND-enabling pre-clinical safety studies, de-risking the clinical development of the Company’s PolyTope® TATX-03 antibody cocktail and its potential to prevent and treat COVID-19. A summary of the positive findings indicates that, through ex... Read More

Diepe IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) is pleased to share that IPA’s subsidiary Biostrand, a Belgian end-to-end multi-omics analysis platform provider, has received a €460,000 round of grant funding from VLAIO (Flanders Innovation & Entrepreneurship), the research fund of the Flemish regional government in Belgium. Conditionally awarded in January this year, BioStrand... Read More

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) is pleased to share the outcome of recent laboratory data on their PolyTope® TATX-03 antibody cocktail, which demonstrates strong neutralizing activity toward the Omicron subvariant BA.2. The BA.2 pseudovirus was neutralized with a potency comparable to the previously analyzed Omicron BA.1, demonstrating ongoing and continued consistency... Read More

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) is pleased to announce that it has completed its previously announced acquisition of control over BioStrand BV, BioKey BV, and BioClue BV (hereinafter collectively referred to as “ BioStrand ”), a group of Belgian biotech entities and pioneers in the field of bioinformatics and biotechnology, through its wholly owned subsidiary... Read More

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) is pleased to announce that it has entered into a definitive share purchase agreement (SPA) to acquire, through its wholly-owned subsidiary ImmunoPrecise Netherlands BV, control over BioStrand BV, BioKey BV, and BioClue BV (hereinafter collectively referred to as “ BioStrand ”), a group of Belgian biotech entities and pioneers in the field... Read More